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ABSTRACT 
Polyvinylpyrrolidone includes soluble and insoluble grades; soluble grades are synthesised by the mechanism of polymerization, the free radical 
polymerization into the water by using hydrogen peroxide as an initiator, the mechanism which terminates the polymerisation reaction makes it 
probable to produce soluble polyvinylpyrrolidone of about any molecular weight. Cross-linked polymer shows yield through popcorn 
polymerisation of an N-vinylpyrrolidone which gets insoluble polyvinylpyrrolidone. Kollidon is in the market as a brand name for 
polyvinylpyrrolidone, a kollidon family now is a set of common excipients based on polyvinylpyrrolidone for use in the pharmaceutical industry. 
They have a great variety of applications in an oral formulation; the functions of oral formulation encompass fast disintegration, sustain drug 
release, solubility, bioavailability enhancement, and stabilize the active ingredient. Kollidon containing a mixture of polyvinyl acetate plus 
povidone are generally used in the formation of sustained release formulation. Owing to their high molecular weight, are recognized as a suitable 
vehicle for producing sustained release drug delivery system. In this review paper, applications of different grades of kollidon are organized in 
the form of tables and reviewed critically. Current literature of patents on kollidon based formulations is also presented. 
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1. INTRODUCTION 
Kollidon grades among the synthetic excipient it is said to be 
one of the essential substances in the pharmaceuticals and 
cosmetic industries. The soluble kollidon grades were 
synthesized by w. reppe in 1939; a number of the product 
followed by including insoluble grades, copolymeristates and 
sustain release preparation for numerous applications. The 
insoluble grades (crospovidone) are prepared using a 
physical cross-linking process as popcorn polymers of vinyl 
pyrrolidone. kollidon VA 64 (Copovidone) is a water-soluble 
copolymeristate of vinylpyrrolidone, and vinyl acetate is 
mainly used as a binder in tablet, granules, capsules, and 
coating process. For sustained release purpose, a mixture of 
polyvinyl acetate and povidone in a ratio of 8:2 is available 
under the name of kollidon SR which mainly used as 
controlled release system. Kollidon soluble grade has a wide 
range of applications in the oral formulation include 
enhancement in solubility and bioavailability of the drug, 
immediate release, taste masking, increase binding capacity, 
stability, improve the activity of pore formation. The 
examples of soluble grade of kollidon (Povidone) are 
kollidon 12 PF, 17 PF, 25, 30, 90F, kollidon VA64 
(Copovidone), insoluble grade (Crospovidone) are kollidon 
CL, CL-F, CL-SF, CL-M and kollidon SR grade which is mixture 
of polyvinyl acetate and povidone in ratio of 8:2 for sustain 
release purpose. All the above grade of kollidon has broad 
application in formulation and development. However, in the 
current review, we have focused critically on applications of 
following grades of kollidon vis kollidon soluble (12PF, 17PF, 
30, 90, VA64), kollidon insoluble (CL-M, CL-F, CL-SF), and 
kollidon SR. The grades on which spacious research has been 
published were selected for review. Hence the objective of 
the present manuscript is to make a compilation review of 
research publications and patents on various applications of 
some chosen grades of kollidon.[1] 
1.1.  Soluble kollidon grades (Povidone) 
The following are the examples of soluble kollidon categories 
such as kollidon 12, 12PF, 17PF, 25, 30, 30LP, 90F. Amongst 
the above categories, Kollidon 12PF, 17PF, 30, 90 were 
selected for review as these having research literature 
published on it. 
1.2. kollidon® 12PF, 17PF 
The low molecular grades, kollidon 12PF, 17PF are intended 
for solubilising agents, dispersants and crystallisation 
inhibitors particularly for injectable  
A current literature review on kollidon 12PF Gayathri K et 
al.  [2] shows that Kollidon 12PF which is having low 
molecular weight polyvinylpyrrolidone generally used as a 
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solubilizing agent and also inhibits crystallization used in the 
preparation of immediate release formulations and also 
reducing printing temperature in 3D printing method in 
order to hold thermolabile and less melting temperature 
drugs. L. S. May et al. [3] prepared a solid dispersion of 
docetaxel utilising binary and ternary method using Kollidon 
12PF, Soluplus, Lutrol F68 and hydroxyl propyl beta-
cyclodextrin in various weight proportions.  Piero Piccioni 
et al. [4] He studied screening systems for initial stage 
formulation development by solubility parameter using the 
solid dispersion of itraconazole with hot melt extrusion and 
quench cooling technique by using kollidon 17PF, Eudragit E 
(EPO) and Soluplus.
 
Table 1: The reported literature on Kollidon 12PF, 17PF. 
Name of 
the drug 
Method Dosage form Result Ref 
Ramipril 
 
 
 
Docetaxel 
Low temperature fused deposition modelling 
(FDM) 3D printing of thermolabile drugs  
 
Binary and ternary solid dispersion 
Drug-loaded 
filament 
 
 
Solid 
dispersion 
Enhance solubility of the 
drug  
 
 
Enhanced solubility of the 
drug 
[5] 
 
 
 
[3] 
 
1.3 Kollidon® 30 
W. Linka. [6] studied the three formulations of matrices 
show the usefulness of Kollidon K30 and HPMC in the 
technology of hydrophilic matrices with ketoprofen, Kollidon 
K30 accelerated the release of ketoprofen from tablets of 
formulation 
1.4 Kollidon® 90F 
Kollidon 90F having various properties like high binding 
capacity the required quantity is 2% or even less, 
stabilisation of oral dosage form, film-forming agent, 
kollidon 90F having good solubility in water and alcohol it 
can be used as a thickener for an aqueous-alcoholic solution 
for oral application 
A current literature review on kollidon 90F A. Fini et al. 
[7]used kollidon90Fwith combination of appropriate 
excipient for obtaining taste masking, orally disintegrating 
tablets and delay the release of ibuprofen using conventional 
and straightforward techniques. Dashevsky et al. [8]he used 
Polyvinylpyrrolidone (Kollidon90F) superior to HPMC and 
HPC as a binder for the swelling layer about binding 
(adherence to capsule) and increase disintegration 
properties of the dosage form. B.B. Alsulays et al. [9]studied 
the influence of the molecular weight of carriers and 
processing parameters on the extrudability, drug release, 
and stability of fenofibrate formulations processed by hot-
melt extrusion. 
 
Table 2: The reported literature on kollidon30, 90F. 
Name of 
the drug 
Method Dosage 
form 
Result Ref 
ketoprofen 
 
ibuprofen 
 
 
 
Direct compression 
 
Orally disintegrating and delayed 
release 
Capsule-Based Drug Delivery 
System with Pulsatile Drug Release 
Tablet 
 
Tablet  
 
Capsule 
 
Enhanced the release of drug from tablet 
 
Delayed the release and masked taste of the bitter drug  
 
Increased binding capacity to adhere capsule 
 
[10] 
 
[7] 
 
1.5 Insoluble kollidon grades(Crospovidone) 
Crospovidone, a hydrophilic crosslinked homopolymer of N-
vinyl pyrrolidone, has been reported as one such alternative. 
Based on its porosity as well as its ability to rapidly absorb 
water, swell, and yet remain insoluble, it is a biologically 
inert, synthetic polymer whose synthesis does not involve 
any organic solvents a polymerisation process in water 
manufactures the Kollidon CL grades without any organic 
solvents. This polymerisation produces a mainly physically 
cross-linked insoluble polyvinylpyrrolidone in the form of a 
popcorn polymer. There are various grades of Kollidon CL, 
CL-F, CL-SF, and CL-M. Among this grade CL-M, CL-F, CL-SF 
was selected because most of the literature are published on 
these grade showing increase in solubility, bioavailability, 
immediate release of drug from dosage, increase sphericity 
of pellets, etc. 
1.6 Kollidon® CL-M 
KollidonCL-Misused as the standard disintegrant for all kind 
of different tablet formulations Main reasons for selection of 
kollidon CL-M is the strongest disintegration power with 
benefits, especially in large tablets. It has advantages 
compared to other disintegrants which are dependent on 
different chemistry due to disintegration and dissolution 
speed.  
A literature review on kollidon CL-M shows that it has been 
used extensively in the formulation of A. Maroni et al. 
[11]studied Preliminary study on free and applied films in 
which Kollidon CL-M was used as superdisintegrant and 
shows the activity of pore-formation in multi-unit pulsatile 
drug delivery system. Y. Gonnissen et al. [12]studied the 
effect of maltodextrins and superdisintegrants on the tablet 
properties and evaluated directly compressible powders co-
processed via spray drying. The disintegration time of tablets 
containing a coprocessed superdisintegrant (kollidon CL-M) 
was longer than other excipients.H. Friedrich et al. 
[13]improved the dissolution rate of carbamazepine and 
nifedipine by adsorbing solutions of the drugs in hydrophilic 
nonvolatile or volatile solvents onto carriers (Aerosil, 
Kollidon CL-M) with a large surface area. 
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Table 3: The reported literature on kollidon CL-M. 
Name of the drug Method Dosage form Result Ref 
Acetaminophen 
 
Acetaminophen 
 
Carbamazepine 
and nifedipine 
Pulsatile drug delivery 
 
Direct compression co-processed 
via spray drying 
 
Absorbent system 
Capsule 
 
Tablet 
 
 
Tablet 
Increase the activity of pore-formation 
 
Increase in disintegration time of 
formulation 
 
Increase the dissolution rate and drug 
release from the formulation 
[14] 
 
[12] 
 
 
[13] 
 
1.7 Kollidon® CL-F, CL-SF 
Kollidon CL-SF is the most excellent crospovidone grade for 
disintegration purposes, and it has a good disintegration 
power and fewer surface defects of the tablets after humid 
storage. This grade is perfect for fast disintegrating buccal 
tablets 
A current literature review on kollidon CL-SF based research 
publication N. C. Loka et al. [15]shows that immediate 
release pellets were prepared by wetted mass extrusion 
method, and markedly improved the sphericity of the pellets 
produced by marumerization. A. Amelian et al. 
[16]formulated orally disintegrating loratadine tablet 
manufactured with co-processed mixture (Kollidon CL-F, CL-
SF) by direct compression method, prepared tablets was of 
appropriate mechanical properties, disintegration time 
below 30 seconds was observed in formulation with 
crospovidone as disintegrant. M. Saurabh et al. [17]studied 
an integrated, quality by design (QbD) approach for design, 
development, and optimization of an orally disintegrating 
tablet formulation of carbamazepine; he found that kollidon 
CL-SF concentration was optimum to prepare orally 
disintegrating tablet formulation of carbamazepine of 
desired attributes; thus it was found to be best sublimating 
agent and disintegrant, respectively. R. Sheshala et al. 
[18]formulated orally disintegrating tablets of sumatriptan 
succinate, the formulation containing kollidon CL-SF 
disintegrated in the oral cavity within 41 s and released 
more than 90% of the drug within15 minute. 
 
Table 4: The reported literature on kollidonCL-F, CL-SF. 
Name of the drug Method Dosage form Result Ref 
Caffeine 
 
Loratadine 
 
 
Carbamazepine 
 
 
Sumatriptane 
succinate 
Extrusion spheronization 
 
Direct compression  
 
 
Direct compression  
 
 
Direct compression 
Pellets 
 
Orally 
disintegrating tablet 
 
Orally 
disintegrating tablet 
 
Orally 
disintegrating tablet 
Improve in sphericity of pellets 
 
Improved mechanical properties of tablet 
and disintegration time 
 
Improved in disintegration time of 
formulation 
 
Improved in disintegration time of 
formulation 
 
[19] 
 
[16] 
 
 
[17] 
 
 
[20] 
 
1.8 Kollidon® SR 
Kollidon SR is spray dried polyvinyl acetate containing also 
soluble poly-vinylpyrrolidone (povidone) in the ratio 8:2, 
kollidon SR is nominally an 80/19 (w/w) mixture of 
polyvinyl acetate and polyvinylpyrrolidone, respectively. 
Kollidon SR can be used for the production of the sustained 
release matrix preparations of tablets, pellets, and granules. 
The recommended technology for the production of 
sustained release matrix tablets based on Kollidon SR is the 
direct compression. The excellent flowability and 
compressibility of KollidonSR are the main factors which 
make this excipient particularly suitable for the manufacture 
of sustained release matrix tablets obtained by direct 
compression 
An updated literature review on Kollidon SR based 
formulations revealed that it could be used in sustaining the 
release, bioavailability enhancement of drugs. M. Shergill et 
al. [21]formulated sustained release solid dispersion oral 
tablet containing water-insoluble drug by using kollidon SR, 
and another excipient, shows enhanced solubility of drug 
while also sustaining its release. Özgüney et al. [22] 
prepared extended release kollidon SR mini-matrices by hot-
melt extrusion, kollidon SR were used as the carrier for drug 
which shows plasticizing effect, and hot-melt extruded 
successfully prepared using kollidon SR. Meulenaar et al. 
[23]kollidon SR used for preparation of an extended-release 
formulation of capecitabine by using In Vitro–In Vivo 
correlating modelling, kollidon SR in this formulation used as 
carrier for spray drying.W. Sakr et al. [24]studied effect of 
Kollidon SR comparison with other polymers on the release 
of Albuterol Sulphate from matrix tablets, he studied 
kollidon SR with combination of (HPMC and Carbopol) were 
found to be potential candidates for the development of 
extended release of Albuterol Sulphate matrix tablets, also 
found that kollidon SR to be a useful release rate modifier for 
highly water-soluble low dose drug. S.H. Song et al. 
[25]formulated controlled-release pelubiprofen tablet using 
kollidonSR, kollidon SR containing formulation was found to 
be the most promising and stable for 6 months in an 
accelerated stability test and 24 months in a long-term 
storage test. Control release achieved from the tablet was 
limited at pH 1.2, but gradually increased at pH6.8 with a 
surface-erosion was studied. Sahoo et al. [26] formulated 
sustained-release dosage form of verapamil hydrochloride 
by solid dispersion technique using eudragit RLPO 
andkollidonSR, drug release study from dosage form was 
studied, kollidon containing dosage form was extended till 8 
hr. J.L. Arias et al. [27] studied the dosage form containing 
kollidon SR colloidal particles which were used as vehicles 
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for oral morphine delivery in pain treatment, also analysed 
that the release studies showed a biphasic profile very 
suitable to achieve a sustained release of morphine during 
24 h. Therefore, they have concluded that kollidon SR 
suspensions are very promising candidates for the 
formulation of oral morphine systems with a sustained 
release. E. Palazi et al. [28]enhanced solubility of water-
insoluble drug felodipine by melt-extrusion process and 
sustained release action of drug was achieved using kollidon 
SR. C. Wiranidchapong et al. [29] investigated the effect of 
storage temperature on drug release from matrices 
containing ibuprofen in Kollidon SR, the matrix tablets were 
produced by direct compression and then kept at 30 and 
45°C for 3 months. Magdalena Czajkowska et al. [30] 
formulated Prolonged-release mini tablets with 
carbamazepine Prolonged release of carbamazepine was 
obtained from both matrix-type by using kollidon SR. S. 
Engineer et al. [31] studied the effects of temperature and 
humidity on tablets containing diphenhydramine 
hydrochloride which was prepared using direct compression 
technique with Kollidon SR; sustained-release tablets 
composed of Kollidon SR have been shown to be heat and 
moisture sensitive. J. Grund et al. [32]studied the kollidon 
SR and other polymer properties on direct compression and 
drug release from water-insoluble controlled release matrix 
tablets and compared with regard to their properties in dry 
and wet state. 
 
 
Table 5: Reported literature on kollidon SR. 
Name of the drug Method Dosage form Result Ref 
Disulfiram 
 
Ibuprofen, 
theophylline 
Capecitabine 
 
Albuterol Sulphate 
 
 
 
Pelubiprofen 
 
 
Verapamil 
hydrochloride 
 
Morphin 
hydrochloride 
 
Felodipine 
 
Ibuprofen 
 
 
Carbamazepine 
 
 
Diphenhydramine 
HCL 
Hot-melt extrusion 
 
Hot-melt extrusion 
 
Spray drying, co-spray drying 
 
Direct compression 
 
 
 
Wet granulation 
 
 
Solid dispersion, tablets were 
compressed with hydraulic 
pellet press. 
Incorporation 
 
Hot-melt extrusion 
 
 
Matrix tablet prepared by 
direct compression  
 
Direct compression 
 
 
Direct compression 
Solid dispersion  
tablets 
Tablet 
 
Tablet 
 
Tablet 
 
 
 
Tablet 
 
 
Tablet 
 
 
Oral Suspension 
 
Amorphous 
solid dispersion 
 
Matrix tablet 
 
 
Matrix mini 
tablet 
 
Tablet 
Enhanced solubility of drug while also 
sustaining its release  
Shows plasticising effect and extended the 
drug release 
Co-spray drying was successfully achieved  
 
Kollidon SR was found to enhance the 
mechanical properties of tablets increasing 
hardness and decreasing friability. 
 
Stability was achieved and controlled the 
release of the tablet at 1.2 pH.  
 
Tablet extends the release of drug till 8hr by 
using kollidon SR.  
 
Sustained the release of drug 
 
Solubility was enhanced as well as sustained 
the release of drug by using kollidon SR.  
 
Stability of ibuprofen seems to be increased 
under various conditions. 
 
Prolonged the release of drug by matrix 
tablet prepared using kollidon SR 
 
shows heat and moisture sensitivity  
[33] 
 
[22] 
 
[23] 
 
[34] 
 
 
 
[35] 
 
 
[36] 
 
 
[27] 
 
[37] 
 
 
[29] 
 
 
[30] 
 
 
[31] 
 
1.9 Kollidon®VA64 (Copovidone) 
The Kollidon VA 64 is manufactured by free-radical 
polymerisation of 6 parts of N-vinylpyrrolidone and 4 parts 
of vinyl acetate in 2-propanol, it has pH 3 – 7 (10 % in 
water), Kollidon VA 64 in formulations for solid dosage 
forms, the particle size distribution can be of considerable 
importance. This particularly applies to the manufacture of 
tablets. However, it also has importants in solutions, e. g. 
film-coating solutions for tablets, as the dissolution rate and 
the dusting properties depend on the proportions of coarse 
and fine particles respectively, it has good binding and film-
forming properties, their affinity to hydrophilic and 
hydrophobic surfaces and the relatively low hygroscopicity. 
Because of these properties, copovidone is used as a binder 
in the production of granules and tablets by wet granulation, 
as a dry binder in direct compression, as film former in 
coatings on tablets, as a protective layer and sub coat for 
tablet cores, as a film-forming agent in sprays and as a 
matrix. 
Current literature review on kollidon VA64 revealed that 
mostly solid dispersions were prepared to increase solubility 
and bioavailability of water-insoluble drugs. K. Chmiel et al. 
[38] identified physically stable concentration of amorphous 
solid dispersion in case of Flutamide with Kollidon VA64. R. 
Dreu et al. [39] formulated multiple-unit tablet containing 
enteric coated pellets by using kollidon VA64 as binder, 
kollidonVA64 was found to be optimal as a cushioning 
excipient. T. Vojinovic et al. [40] prepared ternary solid 
dispersions with hydrophilic polymer kollidon VA64 and 
surface adsorbent for improving dissolution rate of 
carbamazepine, he analyzed that ternary solid dispersion 
prepared with kollidonVA64 hydrophilic polymer and 
adsorption carrier resulted in significant improvement of 
carbamazepine dissolution rate. F.Tres et al. [41]studied the 
pH-dependent controlled release of indomethacin by using 
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kollidonVA64; the experiments were performed at pH 2 to 
mimic the stomach conditions and pH 6.8 to simulate the 
post-stomach conditions. He found that only indomethacin 
present in the 5% extrudate exhibits a detectable dissolution 
rate at pH 2, pointing to a drug release mechanism 
dependent on the highly water-soluble copovidone. He also 
analysed that the proposed pH-dependent dissolution model 
can be applied to a wide range of poorly soluble ionizable 
drugs and may be employed in the future to control and 
modulate the drug release in the stomach and small 
intestine. Maddineni et al. [42] studied, melt extrusion 
technology in combination with Kollidon VA 64 produced 
chemically and physically stable extrudates with higher drug 
loading and enhanced drug release. Nifedipine was found to 
be miscible in Kollidon VA 64 up to 40% w/w drug loading 
without demonstrating the need for any processing aids. R. S. 
Chaudhary et al. [43] kollidon VA 64 and a combination of 
Kollidon VA 64 with Kollidon VA 64 fine as an excipient in 
direct compression process of tablets, the combination of the 
two grades of material was evaluated for capping, 
lamination, and excessive friability. He found that tablets 
with hardness ranging between 19 and 21 kp, with no 
friability, capping, or lamination issue. D. Patel et al. [44] 
formulated user-friendly metered-dose transdermal spray 
(MDTS) of lopinavir; he found that formulation containing 5 
%w/v of Kollidon VA 64 had best sprayability and 
volatilisation property. Significantly increase in permeation 
enhancement and steady-state transdermal flux. K. Kolter et 
al. [45] studied structure and dry binding activity of 
different polymers, including kollidon VA 64, the tablets 
prepared using kollidon VA 64 showed an improvement in 
mechanical properties (hardness, friability) with increasing 
dry binder concentration and greatest binding efficacy. E. 
Castellanos Gil et al. [46] formulated oral controlled 
delivery system for propranolol hydrochloride by using wet 
granulation process. He studied the ability of subcoating 
with Kollidon VA 64 as a barrier to water penetration in 
matrix cores; he observed that kollidon VA 64 not only 
increases the mechanical properties of tablets (less friability) 
but also reduces the amount of absorbed water from the air 
in tropical stability condition. N. Solanki et al. [47] 
formulated 3D printed tablet for rapid drug release by fused 
deposition modelling (FDM): screening polymers for drug 
release, drug-polymer miscibility, and printability, he found 
that mixture of Kollidon VA64 and Affinisol 15 cP is suitable 
polymer system for 3D printing and rapid drug release. 
 
Table 6: The reported literature on kollidon VA 64 
Name of the drug Method Dosage form Result Ref 
Flutamide 
 
 
Carbamazepine 
 
 
Indomethacin 
 
 
Celecoxib 
 
 
Nifedipine 
 
 
 
Esomeprazole 
Magnesium 
 
Lopinavir 
 
 
Dicalcium 
phosphate 
formulation (water-
insoluble) and 
vitamin C (Water 
soluble) was used 
for the study. 
 
Propranolol 
hydrochloride 
 
 
Nimodipine 
 
 
 
Haloperidol 
Solid dispersion  
 
 
Ternary solid dispersion 
 
 
Extrusion spheronization 
 
 
melt-quenching 
 
 
Hot-Melt Extrusion 
 
 
 
Direct compression 
 
 
 
 
 
Direct compression 
 
 
 
 
 
 
 
Wet granulation 
 
 
 
Hot-Melt Extrusion 
 
 
 
Hot-Melt Extrusion 
Amorphous solid 
dispersion 
 
Amorphous solid 
dispersion 
 
Extrudes 
 
 
Amorphous solid 
dispersion 
 
Extrudes 
 
 
 
Tablet 
 
 
Metered-dose 
transdermal spray 
 
Tablet 
 
 
 
 
 
 
 
Tablet 
 
 
 
Solid dispersion 
 
 
 
3D printed tablet 
The amorphous solid dispersion was identified as 
physically stable 
 
The result showed improvement of carbamazepine 
dissolution rate 
 
the pH-dependent controlled release of 
indomethacin was carried out successfully 
 
Increase in bioavailability was determined.  
 
 
Produced physically and chemically stable extrudes 
with enhanced flow characteristics and excellent 
stability.  
 
By using kollidon VA 64 friability, capping, or 
lamination issue were minimised. 
 
Good sprayability, the formulation was stable, and 
the permeation rate was enhanced by using kollidon 
VA 64 
Shows increase in dry binder concentration and 
greatest binding efficacy. 
 
 
 
 
 
 
Kollidon VA 64 increase mechanical properties of 
tablet and also stability 
 
 
Effect of high storage temperature on the 
recrystallisation rate during the dissolution of 
Nimodipine–Kollidon VA64 solid dispersions 
 
Enhanced drug release 
[38] 
 
 
[40] 
 
 
[41] 
 
 
[48] 
 
 
[49] 
 
 
 
[50] 
 
 
[51] 
 
 
[45] 
 
 
 
 
 
 
 
[46] 
 
 
 
[52] 
 
 
 
[53] 
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1.10 Patents on kollidon based formulations 
Patents on kollidon based formulations are presented in 
Table. Patents were filed on the applications of various 
grades of kollidon-vis. These grades were used in the 
formulation of drugs with diverse applications such as 
improvement in solubility, bioavailability, enhanced 
absorption, etc. P. Pilgaonkar et al. [54] patented the novel 
sustained release dosage form comprising an active agent 
and a combination of a non-swelling pH-dependent release 
retardant and a non-swelling pH-independent release 
retardant polymer which provides pH-independent drug 
release for a considerable period of time after 
administration, kollidon SR used as sustained release 
polymer and also other kollidon grades were used in the 
preparation of formulation.V. Kanikanti et al. [55] patented 
solid pharmaceutical formulation with delayed release, the 
invention relates to a solid pharmaceutical preparation with 
delayed release of the active ingredients which is suitable in 
particular for use in animals. Kollidon SR used as delayed 
release polymer in combination with other excipients. K. 
Kolter et al. [56] patented active ingredient-containing 
floating forms comprising polyvinyl acetate and 
polyvinylpyrrolidone, their use, and production, invention 
relates to oral dosage forms comprising one or more active 
ingredients, a formulated mixture of polyvinyl acetate and 
polyvinylpyrrolidone, where appropriate other excipients 
for producing the dosage form, wherein they float on gastric 
fluid and display delayed release of active ingredient. 
Talwar et al. [57] patented an orally administered 
controlled drug delivery system providing temporal and 
spatial control; the Swelling agent belongs to a class of 
compounds known as superdisintegrants(e.g., cross-linked 
polyvinylpyrrolidone) used as an immediate release 
component in the present invention. Roser et al. [58] 
patented rapidly soluble oral solid dosage forms, methods of 
making same, and compositions thereof; in this invention 
kollidon and its grades were used as a binder in the 
formulation. Bockbrader et al. [59] patented solid 
pharmaceutical compositions containing pregabalin; the 
composition includes a matrix forming agent and a swelling 
agent and is suitable for once-daily oral administration. The 
exemplary matrix forming agents include mixtures of 
polyvinyl acetate and polyvinylpyrrolidone, and exemplary 
swelling agents include cross-linked polymers of 
polyvinylpyrrolidone.
 
Table 7: Patents on kollidon based formulations. 
 Title Patent no Date Kollidon grade Inventors 
Novel sustained release dosage form 
 
Solid pharmaceutical formulation 
with delayed release 
 
Active ingredient-containing floating 
forms comprising Polyvinylacetate 
and Polyvinylpyrrolidone, their use 
and production 
 
an orally administered controlled 
drug delivery system providing 
temporal and spatial control 
 
patented rapidly soluble oral solid 
dosage forms, methods of making 
same, and compositions thereof 
 
solid pharmaceutical compositions 
containing pregabalin 
United states patentUS 2009/0053310 A1 
 
United States patent US 2011/0046072 A1. 
 
 
United states patentUS 6,635,279 B2 
 
 
 
 
United States patent US 6,261,601 B1 
 
 
 
United States patent US 5,762,961 
 
 
 
United states patent US 8,945,620 B2 
26/02/2009 
 
24/02/2011 
 
 
21/10/2003 
 
 
 
 
17/07/2001 
 
 
 
09/06/1998 
 
 
 
03/02/2015 
Kollidon SR, VA 64, K30  
 
Kollidon SR 
 
 
Kollidon SR 
 
 
 
 
Kollidon CL-M 
 
 
 
Kollidon VA 64 
 
 
 
Kollidon SR 
[54] 
 
[55] 
 
 
[56] 
 
 
 
 
[57] 
 
 
 
[58] 
 
 
 
[59] 
 
CONCLUSION 
Kollidon is the class of vehicle available in multiple grades. It 
can be used as a carrier in a large variety of formulations 
such as immediate release, sustain release, binder, stabilizer, 
solubility, and bioavailability enhancer, etc. Hence the review 
presented in this paper can be used as a ready source for 
researchers using kollidon in their formulations. 
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